FDA Approves Lipfendra, First Oral PCSK9 Pill, as Trials Cut LDL 56% to 59%
Updated
Updated · Healthline · Aug 3
FDA Approves Lipfendra, First Oral PCSK9 Pill, as Trials Cut LDL 56% to 59%
3 articles · Updated · Healthline · Aug 3
Summary
July 16 FDA approval cleared Lipfendra for adults with high LDL cholesterol, making it the first oral PCSK9 inhibitor and a once-daily option that can be used with or instead of statins.
Two pivotal trials showed Lipfendra lowered LDL by about 56% after 24 weeks in one study and 59% in the other, though they did not test whether it reduces heart attacks or strokes.
Nine randomized trials in a new meta-analysis found twice-yearly inclisiran reduced LDL 49% more than placebo, reinforcing another nonstatin option for patients who cannot reach targets or struggle with daily adherence.
2026 cholesterol guidelines from the AHA, ACC and other groups push earlier treatment, lower LDL targets for higher-risk patients, lipoprotein(a) testing and updated risk scoring.
New studies tied to those guidelines suggest more than half of U.S. adults may now qualify for statins, signaling a broader shift toward earlier and more personalized cholesterol care.